

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ANGELALIGN TECHNOLOGY INC.

時代天使科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6699)

(1) RE-DESIGNATION OF A DIRECTOR AND APPOINTMENT OF THE PRESIDENT OF GLOBAL BUSINESS (EX-CHINA)

AND

(2) APPOINTMENT OF THE CHIEF OPERATING OFFICER

The Board announces that:

- (1) Mr. HUANG Kun, a non-executive Director of the Company, has been re-designated and appointed as an executive Director and the president of global business (ex-China) of the Company with effect from September 1, 2023; and
- (2) Mr. SONG Xin, an executive Director of the Company, has been promoted from the chief commercial officer of the Company to the chief operating officer of the Company with effect from September 1, 2023.

RE-DESIGNATION OF A DIRECTOR AND APPOINTMENT OF THE PRESIDENT OF GLOBAL BUSINESS (EX-CHINA)

The board (the “**Board**”) of directors (the “**Director(s)**”) of Angelalign Technology Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. HUANG Kun (黃琨) (“**Mr. Huang**”), a non-executive Director, has been re-designated and appointed to be an executive Director and the president of global business (ex-China) of the Company with effect from September 1, 2023.

Mr. Huang has served as a Director of the Company for years and is familiar with the Company’s business and development strategies. He has been driving and leading the Company’s internationalization strategies since the listing of the Company and very involved in the global business operation and expansion of the Company. Mr. Huang, as a partner of CareCapital, has been playing an instrumental role in strategy planning and international business expansion for both CareCapital and its portfolio companies, and maintaining an extensive network with enterprises and key opinion leaders (KOLs) in the global dental industry. He is also the co-chairman of the board of International Orthodontics Foundation Limited (國際正畸基金會), an influential not-for-profit international research and education organization devoted to improving orthodontic care worldwide. The Company strives to become a worldwide leader in the field of digital orthodontics. The Board believes that the experience and background of Mr. Huang is highly compatible with the Company’s development strategy in globalization and will benefit the future development of the Company.

The biographical details of Mr. Huang are as follows:

Mr. HUANG Kun (黃琨), aged 41, will serve as an executive Director and the president of global business (ex-China) of the Company with effect from September 1, 2023. Prior to his re-designation, Mr. Huang joined the Group in January 2015 as a director of Wuxi EA Medical Instruments Technologies Limited (無錫時代天使醫療器械科技有限公司) (“**Wuxi EA**”) and was appointed as a non-executive Director in November 2018 and a member of the remuneration committee of the Board (the “**Remuneration Committee**”) in June 2021. He also serves as a director of certain of subsidiaries of the Company, including Wuxi EA, the major operating entity of the Group in China, and Angelalign Technology Pte. Ltd., the major international business operating entity of the Group.

Mr. Huang joined CareCapital Advisors Limited (松柏投資管理(香港)有限公司), a global investment firm focusing on quality-of-life healthcare with oral health as a core focus in April 2015 and serves as a partner. Mr. Huang is the co-chairman of the board of International Orthodontics Foundation Limited (國際正畸基金會), a not-for-profit research and education organization devoted to improving orthodontic care worldwide.

Prior to that, Mr. Huang served as a vice president of Beijing Warburg Pincus Consulting Co., Ltd. (北京華平投資諮詢有限公司) from July 2011 to March 2015 and as a senior investment manager of Orchid Asia Investment Consulting (Shanghai) Co., Ltd. (蘭馨投資諮詢(上海)有限公司) from June 2007 to June 2011.

Mr. Huang graduated from Tsinghua University (清華大學) with a bachelor’s degree in finance in July 2005.

Mr. Huang has indirectly owned 717,200 shares of the Company through his wholly-owned company and is deemed to be interested in such shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

Mr. Huang has entered into a service contract with the Company for an initial term of three years commencing from September 1, 2023. Mr. Huang will be subject to retirement by rotation and re-election in accordance with the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) and the articles of association of the Company. Mr. Huang will receive remuneration as an executive Director to be determined by the Board with reference to the recommendation of the Remuneration Committee based on his duties and responsibilities with the Company, his experience and the prevailing market conditions. Mr. Huang will retain as a member of the Remuneration Committee, and will abstain from voting for determining on his remuneration by either of the Remuneration Committee or the Board, as applicable, in accordance with the Listing Rules and relevant terms of references.

Save as disclosed above, Mr. Huang has confirmed that he (i) has not held any directorship in any other public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years preceding the date of this re-designation; (ii) does not have any interest in any shares, underlying shares or debentures of the Company within the meaning of Part XV of the SFO; (iii) does not hold any other positions in the Company or its subsidiaries; and (iv) does not have any relationship with any other Directors, senior management, substantial shareholders or controlling shareholders (as respectively defined in the Listing Rules) of the Company.

Save as disclosed in this announcement, there are no other matters which need to be brought to the attention of the shareholders of the Company regarding the re-designation of Mr. Huang or any other information relating to Mr. Huang that needs to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules.

The Board would like to take this opportunity to express its warmest welcome to Mr. Huang on his new positions in the Company.

APPOINTMENT OF THE CHIEF OPERATING OFFICER

The Board announces that Mr. SONG Xin (宋鑫) (“**Mr. Song**”), an executive Director, has been promoted from the chief commercial officer of the Company to the chief operating officer of the Company with effect from September 1, 2023.

Mr. Song has served as a Director of the Company for years and is familiar with the Company’s business and development strategies, primarily responsible for the sales, marketing and treatment planing operation. The Board believes that the experience and background of Mr. Song are highly compatible with the Company’s development strategy and will benefit the future development of the Company.

The biographical details of Mr. Song are as follows:

Mr. SONG Xin (宋鑫), aged 37, is an executive Director and a member of the nomination committee of the Board, and has been appointed as the chief operating officer of the Company with effect from September 1, 2023. Prior to his appointment, Mr. Song joined the Group in August 2011, and has been served as the chief commercial officer of the Company since February 2018 and an executive Director since April 2021. He also serves as a director of certain of subsidiaries of the Company, including Wuxi EA, the major operating entity of the Group in China, and Angelalign Technology Pte. Ltd., the major international business operating entity of the Group.

Prior to that, Mr. Song had served as a regional manager of Guizhou Tongjitang Pharmaceutical Co., Ltd (貴州同濟堂製藥有限公司) from March 2009 to July 2011.

Mr. Song obtained his bachelor’s degree in bio-technology from Henan University of Technology (河南工業大學) in July 2008 and is currently pursuing EMBA degree from Fudan University (復旦大學).

Mr. Song has been granted with 600,000 options (each option shall entitle him to subscribe for one share of the Company) under the Post-IPO Share Option Scheme of the Company. Please refer to the announcements of the Company dated April 28, 2023 and May 4, 2023 for details. Mr. Song has also indirectly owned 1,415,300 shares of the Company through his wholly-owned company. Mr. Song is deemed to be interested in such shares within the meaning of Part XV of the SFO.

Save as disclosed above, Mr. Song has confirmed that he (i) has not held any directorship in any other public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years preceding the date of this re-designation; (ii) does not have any interest in any shares, underlying shares or debentures of the Company within the meaning of Part XV of the SFO; (iii) does not hold any other positions in the Company or its subsidiaries; and (iv) does not have any relationship with any other Directors, senior management, substantial shareholders or controlling shareholders (as respectively defined in the Listing Rules) of the Company.

Save as disclosed in this announcement, there are no other matters which need to be brought to the attention of the shareholders of the Company regarding the appointment of Mr. Song or any other information relating to Mr. Song that needs to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules.

The Board would like to take this opportunity to express its warmest welcome to Mr. Song on his new position in the Company.

By Order of the Board
Angelalign Technology Inc.
Mr. FENG Dai
Chairman

Hong Kong, August 24, 2023

As at the date of this announcement, the Board comprises Mr. HU Jiezhong, Mr. SONG Xin, and Ms. DONG Li as executive Directors; Mr. FENG Dai and Mr. HUANG Kun as non-executive Directors; Mr. HAN Xiaojing, Mr. SHI Zi and Mr. ZHOU Hao as independent non-executive Directors.